drugset / Trial / NCT01534637
Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer
Phase 2
Completed
22 enrolled
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelSupportive care
Summary
This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer. Antiemetic drugs, such as aprepitant may help lessen or prevent nausea and vomiting in patients receiving chemotherapy and radiation therapy
Timeline
- Start
- 2006-08
- Primary completion
- 2009-12
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | Intravenous |
| Background | Capecitabine | Small molecule | — | Oral |